China Orders Pfizer And Wyeth To Divest Certain Operations As Condition To Merger Approval
This article was originally published in The Pink Sheet Daily
Executive Summary
Merger watchers were keeping close tabs on whether one-year-old Anti-Monopoly Law would be used to block deal in China; divestments include an animal vaccine business.
You may also be interested in...
68 Billon Dollar Question: Could China's Government Block Worldwide Merger Of Wyeth And Pfizer?
BEIJING - Tucked away toward the end of the $68-billion merger agreement between Pfizer Inc. and Wyeth is a clause that could give the Chinese government the ultimate power to approve or block this worldwide union of American pharmaceutical giants
Global Pharma Giants Concered About China’s New Anti-Monopoly Law
BEIJING - Leading executives at multinational firms operating in China, including some pharmaceutical giants, are concerned that the country's new anti-monopoly law could be used to counter strong market positions or to forced licensing of innovative products to competitors
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.